Pharmacological blockade of
N-acylethanolamine acid amidase (NAAA) activity is an available approach for
inflammation and
pain control through restoring the ability of endogenous PEA. But the recently reported NAAA inhibitors suffer from the chemical and
biological unstable properties, which restrict functions of NAAA inhibition in vivo. It is still unrevealed whether systematic inhibition of NAAA could modulate PEA-mediated
pain signalings. Here we reported an
oxazolidinone imide compound 3-(6-phenylhexanoyl)
oxazolidin-2-one (F96), which potently and selectively inhibited NAAA activity (IC50 = 270 nM). Intraperitoneal (i.p.) injection of F96 (3-30 mg/kg) dose-dependently reduced ear
edema and restored PEA levels of ear tissues in 12-O-Tetradecanoylphorbol-13-acetate (TPA) induced ear
edema models. Furthermore, F96 inhibited
acetic acid-induced writhing and increased spared nerve injury induced
tactile allodynia thresholds in a dose-dependent manner. Pharmacological effects of F96 (10 mg/kg, i.p.) on various animal models were abolished in
PPAR-α(-/-) mice, and were prevented by
PPAR-α antagonist
MK886 but not by canabinoid receptor type 1 (CB1) antagonist
Rimonabant nor canabinoid receptor type 2 (CB2) antagonist
SR144528. Zebrafish embryos experiments showed better security and lower toxicity for F96 than
ibuprofen. These results revealed that F96 might be useful in treating inflammatory and
neuropathic pain by NAAA inhibition depending on
PPAR-α receptors.